pSivida (ASX:PVA), a company leading in the development of sustained release drug products and technologies, announced an abstract supporting its Durasert three-year treatment for posterior segment uveitis has been accepted for a paper presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting being held in Baltimore from 7-11 May.
The abstract accepted for paper presentation is titled, 'An Injectable Fluocinolone Acetonide Intravitreal Insert Decreases the Incidence of Recurrence in Patients with Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye: 12 Month Results'.
The data will be presented by Dr Glenn Jaffe, Robert Machemer Professor of Ophthalmology at Duke University School of Medicine, during the session titled, 'Emerging Treatments for Uveitis'.
"ARVO is one of the most important ophthalmology conferences of the year and we are excited that data from our Phase 3 study has been selected," said Nancy Lurker, President and CEO. "Dr. Jaffe is a recognised authority on posterior segment uveitis and we are looking forward to his presentation to this prestigious audience."
Posterior segment uveitis is a chronic, non-infectious inflammatory disease affecting the posterior segment of the eye, often involving the retina, which is a leading cause of blindness in the developed and developing countries. It afflicts people of all ages, producing swelling and destroying eye tissues, which can lead to severe vision loss and blindness.
